

# Neil M Walker

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2296961/neil-m-walker-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16  
papers

987  
citations

11  
h-index

18  
g-index

18  
ext. papers

1,220  
ext. citations

11.1  
avg, IF

2.86  
L-index

#	Paper	IF	Citations
16	Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. <i>Nature Genetics</i> , <b>2015</b> , 47, 381-6	36.3	414
15	Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. <i>Nature Genetics</i> , <b>2009</b> , 41, 1011-5	36.3	224
14	Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. <i>Nature Genetics</i> , <b>2015</b> , 47, 839-46	36.3	97
13	Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002139	11.6	76
12	Dissection of a Complex Disease Susceptibility Region Using a Bayesian Stochastic Search Approach to Fine Mapping. <i>PLoS Genetics</i> , <b>2015</b> , 11, e1005272	6	42
11	Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. <i>BMJ Open</i> , <b>2014</b> , 4, e005559	3	26
10	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	26
9	Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. <i>BMJ Open</i> , <b>2015</b> , 5, e009799	3	16
8	A genome-wide assessment of the role of untagged copy number variants in type 1 diabetes. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004367	6	16
7	Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. <i>Wellcome Open Research</i> , <b>2017</b> , 2, 28	4.8	13
6	Detection and correction of artefacts in estimation of rare copy number variants and analysis of rare deletions in type 1 diabetes. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 1774-90	5.6	11
5	The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	11
4	Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). <i>Trials</i> , <b>2015</b> , 16, 86	2.8	9
3	Returning findings within longitudinal cohort studies: the 1958 birth cohort as an exemplar. <i>Emerging Themes in Epidemiology</i> , <b>2014</b> , 11, 10	3.9	3
2	A rare IL2RA haplotype identifies SNP rs61839660 as causal for autoimmunity		2
1	Coagulation Factor V is a T cell inhibitor expressed by leukocytes in COVID-19.. <i>IScience</i> , <b>2022</b> , 103971	6.1	1